Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer

Launched by MAYO CLINIC · Jul 6, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how different factors before testing can affect the analysis of circulating tumor DNA (ctDNA) in women with early and locally advanced breast cancer. ctDNA is tiny pieces of cancer DNA that can be found in the blood. The study aims to understand how things like the type of blood collection tubes used, how quickly the blood is processed, and the conditions under which samples are stored can impact the measurement of ctDNA. If these factors aren’t handled properly, it can lead to inaccurate results, making it harder for doctors to detect cancer.

To participate in this trial, women must be over 18 years old and have been diagnosed with stage I, II, or III breast cancer. Unfortunately, those with stage IV breast cancer or other active cancers (except certain skin cancers) cannot join. Participants will be asked to provide consent and will have their blood and tissue samples collected for research. This study is currently recruiting, and it aims to improve the understanding of how to best collect and handle samples from breast cancer patients, which may help in future cancer research and treatment.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • All women \> 18 years of age
• • Stage I-III breast cancer
• • Subject has consented to IRB 2130-00 Tissue Registry
• Exclusion Criteria:
• • Stage IV breast cancer
• • Unwilling or unable to give consent
• • Unable to participate for 1 year
• • No one with a concurrent cancer except those diagnosed with an in situ cancer or non-melanoma skin cancer